Safety and efficacy of aprotinin under conditions of deep hypothermia and circulatory arrest

Daniel J. Goldstein, Carolyn M. DeRosa, Linda B. Mongero, Alan D. Weinberg, Robert E. Michler, Eric A. Rose, Mehmet C. Oz, Craig R. Smith

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

Aprotinin has been successfully used to reduce blood loss and blood product requirements in patients undergoing primary and reoperative cardiac operations. Its safety and efficacy during profound hypothermia and circulatory arrest have been questioned, however. A retrospective review compared 24 patients who received aprotinin during complex aortic procedures under profound hypothermia and circulatory arrest with 24 age-matched patients undergoing similar procedures without aprotinin. Activated clotting time was maintained at longer than 500 seconds (kaolin activating agent) or longer than 750 seconds (celite). We observed no statistically significant difference in the incidence of neurologic events ( p not significant) or myocardial infarctions ( p not significant), and there was a trend toward reduced in-hospital mortality rate in aprotinin-treated patients. A higher incidence of postoperative renal dysfunction was encountered in aprotinin-treated patients. Aprotinin recipients had a significant reduction in requirements for postoperative homologous erythrocytes ( p = 0.01). We conclude that aprotinin may be safely and effectively used in patients undergoing deep hypothermia and circulatory arrest. (J THORAC CARDIOVASC SURG 1995;110:1615-22).

Original languageEnglish (US)
Pages (from-to)1615-1621
Number of pages7
JournalThe Journal of thoracic and cardiovascular surgery
Volume110
Issue number6
DOIs
StatePublished - 1995
Externally publishedYes

Fingerprint

Aprotinin
Hypothermia
Safety
Diatomaceous Earth
Kaolin
Incidence
Hospital Mortality
Nervous System
Erythrocytes
Myocardial Infarction
Kidney
Mortality

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Pulmonary and Respiratory Medicine
  • Surgery

Cite this

Safety and efficacy of aprotinin under conditions of deep hypothermia and circulatory arrest. / Goldstein, Daniel J.; DeRosa, Carolyn M.; Mongero, Linda B.; Weinberg, Alan D.; Michler, Robert E.; Rose, Eric A.; Oz, Mehmet C.; Smith, Craig R.

In: The Journal of thoracic and cardiovascular surgery, Vol. 110, No. 6, 1995, p. 1615-1621.

Research output: Contribution to journalArticle

Goldstein, Daniel J. ; DeRosa, Carolyn M. ; Mongero, Linda B. ; Weinberg, Alan D. ; Michler, Robert E. ; Rose, Eric A. ; Oz, Mehmet C. ; Smith, Craig R. / Safety and efficacy of aprotinin under conditions of deep hypothermia and circulatory arrest. In: The Journal of thoracic and cardiovascular surgery. 1995 ; Vol. 110, No. 6. pp. 1615-1621.
@article{c114ce554be84111b8ca348f8c3650bd,
title = "Safety and efficacy of aprotinin under conditions of deep hypothermia and circulatory arrest",
abstract = "Aprotinin has been successfully used to reduce blood loss and blood product requirements in patients undergoing primary and reoperative cardiac operations. Its safety and efficacy during profound hypothermia and circulatory arrest have been questioned, however. A retrospective review compared 24 patients who received aprotinin during complex aortic procedures under profound hypothermia and circulatory arrest with 24 age-matched patients undergoing similar procedures without aprotinin. Activated clotting time was maintained at longer than 500 seconds (kaolin activating agent) or longer than 750 seconds (celite). We observed no statistically significant difference in the incidence of neurologic events ( p not significant) or myocardial infarctions ( p not significant), and there was a trend toward reduced in-hospital mortality rate in aprotinin-treated patients. A higher incidence of postoperative renal dysfunction was encountered in aprotinin-treated patients. Aprotinin recipients had a significant reduction in requirements for postoperative homologous erythrocytes ( p = 0.01). We conclude that aprotinin may be safely and effectively used in patients undergoing deep hypothermia and circulatory arrest. (J THORAC CARDIOVASC SURG 1995;110:1615-22).",
author = "Goldstein, {Daniel J.} and DeRosa, {Carolyn M.} and Mongero, {Linda B.} and Weinberg, {Alan D.} and Michler, {Robert E.} and Rose, {Eric A.} and Oz, {Mehmet C.} and Smith, {Craig R.}",
year = "1995",
doi = "10.1016/S0022-5223(95)70021-8",
language = "English (US)",
volume = "110",
pages = "1615--1621",
journal = "Journal of Thoracic and Cardiovascular Surgery",
issn = "0022-5223",
publisher = "Mosby Inc.",
number = "6",

}

TY - JOUR

T1 - Safety and efficacy of aprotinin under conditions of deep hypothermia and circulatory arrest

AU - Goldstein, Daniel J.

AU - DeRosa, Carolyn M.

AU - Mongero, Linda B.

AU - Weinberg, Alan D.

AU - Michler, Robert E.

AU - Rose, Eric A.

AU - Oz, Mehmet C.

AU - Smith, Craig R.

PY - 1995

Y1 - 1995

N2 - Aprotinin has been successfully used to reduce blood loss and blood product requirements in patients undergoing primary and reoperative cardiac operations. Its safety and efficacy during profound hypothermia and circulatory arrest have been questioned, however. A retrospective review compared 24 patients who received aprotinin during complex aortic procedures under profound hypothermia and circulatory arrest with 24 age-matched patients undergoing similar procedures without aprotinin. Activated clotting time was maintained at longer than 500 seconds (kaolin activating agent) or longer than 750 seconds (celite). We observed no statistically significant difference in the incidence of neurologic events ( p not significant) or myocardial infarctions ( p not significant), and there was a trend toward reduced in-hospital mortality rate in aprotinin-treated patients. A higher incidence of postoperative renal dysfunction was encountered in aprotinin-treated patients. Aprotinin recipients had a significant reduction in requirements for postoperative homologous erythrocytes ( p = 0.01). We conclude that aprotinin may be safely and effectively used in patients undergoing deep hypothermia and circulatory arrest. (J THORAC CARDIOVASC SURG 1995;110:1615-22).

AB - Aprotinin has been successfully used to reduce blood loss and blood product requirements in patients undergoing primary and reoperative cardiac operations. Its safety and efficacy during profound hypothermia and circulatory arrest have been questioned, however. A retrospective review compared 24 patients who received aprotinin during complex aortic procedures under profound hypothermia and circulatory arrest with 24 age-matched patients undergoing similar procedures without aprotinin. Activated clotting time was maintained at longer than 500 seconds (kaolin activating agent) or longer than 750 seconds (celite). We observed no statistically significant difference in the incidence of neurologic events ( p not significant) or myocardial infarctions ( p not significant), and there was a trend toward reduced in-hospital mortality rate in aprotinin-treated patients. A higher incidence of postoperative renal dysfunction was encountered in aprotinin-treated patients. Aprotinin recipients had a significant reduction in requirements for postoperative homologous erythrocytes ( p = 0.01). We conclude that aprotinin may be safely and effectively used in patients undergoing deep hypothermia and circulatory arrest. (J THORAC CARDIOVASC SURG 1995;110:1615-22).

UR - http://www.scopus.com/inward/record.url?scp=0028841180&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028841180&partnerID=8YFLogxK

U2 - 10.1016/S0022-5223(95)70021-8

DO - 10.1016/S0022-5223(95)70021-8

M3 - Article

VL - 110

SP - 1615

EP - 1621

JO - Journal of Thoracic and Cardiovascular Surgery

JF - Journal of Thoracic and Cardiovascular Surgery

SN - 0022-5223

IS - 6

ER -